Department of Ophthalmology, University Vita-Salute, IRCCS San Raffaele, Milan, Italy.
Eye Clinic, Department of Neurological and Movement Sciences, University of Verona, Verona, Italy.
Eye (Lond). 2018 Jan;32(1):55-66. doi: 10.1038/eye.2017.290. Epub 2017 Dec 21.
PurposeTo correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (ie oral eplerenone, half-fluence photodynamic therapy (PDT)).Patients and methodsTwenty eyes of 16 consecutive patients with treatment-naïve CSC undergoing either eplerenone or PDT were enrolled in this prospective, observational study. All patients underwent structural OCT and OCT-A at baseline and after therapy at months 1 and 3.ResultsEleven eyes of nine patients and nine eyes of seven patients underwent eplerenone or PDT treatment, respectively. Central macular thickness (CMT) and subretinal fluid (SRF) correlated to fovea avascular zone (FAZ) area (r=0.74 and r=0.71, P=0.01) and vessel density (r=0.77 and r=0.68, P=0.01) at deep capillary plexus (DCP). CMT (P=0.0011), SRF (P=0.0005), SFCT (P=0.0016), FAZ area at DCP (P=0.0334) improved at 3-month visit. A significant reduction of deep FAZ area was appreciated in eplerenone (P=0.0204) but not in PDT (P=0.5) group. SFCT reduction was significantly higher in PDT than eplerenone group (P=0.0347).ConclusionStructural and vascular parameters are correlated in CSC and they improve after different treatments. Both half-fluence PDT and oral eplerenone do not permanently damage choriocapillaris or other choroidal layers as evaluated by OCT-A.
将功能和结构光相干断层扫描(OCT)与患有中心性浆液性脉络膜视网膜病变(CSC)患者的光相干断层扫描血管造影(OCT-A)测量结果相关联,并描述这些患者在接受治疗(即口服依普利酮、半剂量光动力疗法(PDT))后的变化。
本前瞻性观察研究纳入了 16 例初治 CSC 患者的 20 只眼,这些患者分别接受依普利酮或 PDT 治疗。所有患者均在基线和治疗后 1 个月和 3 个月时接受结构 OCT 和 OCT-A 检查。
9 例患者的 11 只眼和 7 例患者的 9 只眼分别接受了依普利酮或 PDT 治疗。中央黄斑厚度(CMT)和视网膜下液(SRF)与黄斑无血管区(FAZ)面积(r=0.74 和 r=0.71,P=0.01)和深层毛细血管丛(DCP)血管密度(r=0.77 和 r=0.68,P=0.01)相关。在 3 个月时,CMT(P=0.0011)、SRF(P=0.0005)、SFCT(P=0.0016)、DCP 处 FAZ 面积(P=0.0334)均得到改善。依普利酮组(P=0.0204),而 PDT 组(P=0.5)的深层 FAZ 面积显著减小。与依普利酮组相比,PDT 组的 SFCT 降低更显著(P=0.0347)。
CSC 的结构和血管参数相关,不同治疗后均得到改善。半剂量 PDT 和口服依普利酮均不会像 OCT-A 评估的那样对脉络膜毛细血管或其他脉络膜层造成永久性损伤。